Loading...
Market
Story
Novo Nordisk's Semaglutide 7.2 mg Achieves 20.7% Weight Loss in STEP UP Trial, 18.7% Overall in 1,407 Participants
Jan 17, 2025, 12:20 PM
Novo Nordisk A/S announced that its STEP UP trial for semaglutide 7.2 mg demonstrated a primary endpoint achievement with a statistically significant weight loss of 20.7% after 72 weeks of treatment. This result was achieved with treatment adherence among participants, who averaged a weight loss of 20.7%. In cases of broader treatment considerations, the average weight loss was reported at 18.7%. The trial involved 1,407 participants with obesity. In comparison, semaglutide 2.4 mg resulted in a weight loss of 17.5%, while placebo participants lost an average of 2.4%. The STEP UP trial results are positioned against Eli Lilly's Zepbound, which recorded a 23% weight loss over 176 weeks, according to data from August 2024.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Wegovy gains market share over Zepbound • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Yes • 50%
No • 50%
More than $3 billion • 25%
$2 billion to $3 billion • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
No • 50%
Yes • 50%
More than 2 million • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%